Learn about the groundbreaking cardiovascular care offered at the Mount Sinai Health System. Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked No. 4 in the nation for Cardiology, Heart and Vascular Surgery by U.S. News & World Report® for 2024-25, and is recognized internationally as a leader in advancing all aspects of cardiology care, cardiac surgery, and cardiovascular research. Our team of award-winning physicians is expanding the field of knowledge in cardiovascular medicine, including treatments for arrhythmias, coronary artery disease, heart failure, valvular disease, and vascular disease.
Learn about the groundbreaking cardiovascular care offered at the Mount Sinai Health System. Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked No. 4 in the nation for Cardiology, Heart and Vascular Surgery by U.S. News & World Report® for 2024-25, and is recognized internationally as a leader in advancing all aspects of cardiology care, cardiac surgery, and cardiovascular research. Our team of award-winning physicians is expanding the field of knowledge in cardiovascular medicine, including treatments for arrhythmias, coronary artery disease, heart failure, valvular disease, and vascular disease.
Cardiology Content |view more
Celebrating Dr. Valentín Fuster's Contributions to Cardiovascular Medicine and Science
JACC's Tribute Video Celebrates Valentín Fuster, MD at ACC.24
The multisite—and possibly paradigm-shifting—study will assess whether pairing coronary CT angiography with an AI-enabled algorithm to classify the build-up of atherosclerotic plaque into stages is superior to the standard of care.
Join Mount Sinai for "The Top Ten Topics in Clinical Cardiology"
Friday, November 1st, 2024 Stern Auditorium The Mount Sinai Hospital New York, NY
The new clinical trial, led by Valentín Fuster, MD, PhD, is responding to clinical evidence that the atherosclerotic process starts early in life, and even in young adults deemed otherwise healthy can pave the way for cardiovascular events.
Stopping Aspirin One Month After PCI Is Found Safe in Patients With Acute Coronary Syndromes
Withdrawing aspirin one month after PCI in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to dual antiplatelet therapy, the current standard of care.
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
Mount Sinai study shows how the heart and brain interact to influence sleep patterns and help with recovery
Routine use of an orbital atherectomy device to remove calcium from severely blocked coronary arteries before patients undergo cardiac stenting procedures does not improve outcomes, a Mount Sinai-led study has found.
The progression of atherosclerosis in people who have no symptoms of it is independently associated with the risk of dying from any cause, according to a new study led by researchers from Mount Sinai Fuster Heart Hospital, published September ...
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
Roxana Mehran, MD, Is Incoming Vice President of the American College of Cardiology
Roxana Mehran, MD, Professor of Medicine (Cardiology), and Population Health Science and Policy of Mount Sinai Fuster Heart Hospital, has been named the incoming Vice President of the American College of Cardiology (March 2025).
Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF), according to the largest study of its kind on this new technology, led by the Icahn School of Medicine at Mount Sinai.
Mount Sinai Fuster Heart Hospital: 2023 Clinical Outcomes and Innovations Report
The Cardiac Catheterization Laboratory at The Mount Sinai Hospital is among the highest volume centers, yet also among the safest interventional catheterization laboratories in the United States.
New AI Tool Finds Rare Variants Linked to Heart Disease in 17 Genes
Using an advanced artificial intelligence tool, researchers at the Icahn School of Medicine at Mount Sinai have identified rare coding variants in 17 genes that shed light on the molecular basis of coronary artery disease (CAD), the leading ...
The European Society for Clinical Investigation (ESCI) is awarding Valentin Fuster, MD, PhD, President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, its ESCI Distinguished Medal for 2024. He received this honor ...
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol ...
Valentín Fuster, MD, PhD, MACC, President of Mount Sinai Fuster Heart Hospital, was awarded the WHF Lifetime Achievement Award 2024 from the World Heart Federation to publicly recognize his remarkable contributions to the mission of the ...
Breakthrough study led by Mount Sinai researcher could change standard-of-care guidelines to improve outcomes
ACC Cardiology Hour From ACC.24
Dr. Fuster leads a panel discussion on clinical trials presented at ACC.24
A neural network-based electrocardiogram (ECG) interpretation algorithm developed at Mount Sinai is designed to predict the presence of right ventricular dilation and dysfunction based on cardiac magnetic resonance imaging (MRI) reference ...
Mount Sinai Fuster Heart Hospital 2024
Mount Sinai Fuster Heart Hospital is renowned internationally in all facets of cardiology care, cardiac surgery, and advanced research. Global leaders in cardiology, the team of award-winning physicians has invigorated the science of cardiovascular ...
For Mount Sinai Fuster Heart Hospital, 2023 was truly a landmark year. The foremost landmark is our new name: In October, Mount Sinai Heart was renamed to honor Valentin Fuster, MD, PhD, the man who built Mount Sinai’s cardiovascular program ...
Research Advances a Promising Pathway of Treatment for Patients With Severe Hypercholesterolemia
A therapeutic pathway targeting ANGPTL3 holds promise for patients with severe hypercholesterolemia who do not achieve their low-density lipoprotein cholesterol thresholds despite treatment with lipid-lowering therapies.
Investigators at CVRI continued to advance discovery and innovation in lifestyle and prevention, systems physiology and bioengineering, and genetic medicine.
The team has significantly advanced knowledge on psychosocial stress and cardiovascular disease by identifying connections between the nervous, immune, and vascular systems.
The three-drug cardiovascular polypill, developed and studied under the leadership of Valentin Fuster, MD, PhD, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing ...
Two Breakthrough Devices Debut in The Mount Sinai Hospital Cardiac Catheterization Lab
The Cardiac Catheterization Laboratory at The Mount Sinai Hospital pioneered two innovative procedures. The first involved employing the world’s smallest heart pump system to provide temporary mechanical circulatory support during high-risk ...
George Dangas, MD, PhD, Named President of Society for Cardiovascular Angiography and Interventions
Dr. Dangas, Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at Icahn Mount Sinai and Chief of Cardiology at Mount Sinai Queens, is the 46th president of SCAI.
The clinics work closely with the Dubin Breast Center and the Cardio-Oncology Program, drawing on Mount Sinai’s network of specialists and resources.
Study Shows Fasting Can Trigger a Negative Effect on Monocytes and Inflammation in Mouse Models
The mechanistic study could lead to a better understanding of how chronic fasting may affect the body long term.
TAVR Procedures at The Mount Sinai Hospital Win Highest Rating From STS/ACC Registry
The Cardiac Catheterization Laboratory at The Mount Sinai Hospital has received for the third consecutive year the highest three-star rating, one of the most rigorous and highly respected measures for evaluating the quality of transcatheter ...
Advancing Awareness, Diagnosis, and Treatment for hATTR Amyloidosis Cardiomyopathy
Hereditary transthyretin amyloidosis significantly increases the risk of heart disease and disproportionately affects African American and LatinX people in the United States, yet few members of the public are aware of it.
Mount Sinai Heart Is Now the Mount Sinai Fuster Heart Hospital
The name change honors Valentin Fuster, MD, PhD, who built Mount Sinai’s cardiovascular program into one of the world’s leading heart centers while advancing cardiovascular medicine around the globe.
Mount Sinai Health System announced on 10/26/23 that “Mount Sinai Fuster Heart Hospital” is the new name for its top-ranked heart service, formerly known as Mount Sinai Heart.
Mount Sinai’s Krishna Patel, MD, and Team Demonstrate Efficacy of Cardiac PET CT
PET MPI quantifies left ventricular ejection fraction (LVEF) at peak stress, offering diagnostic and prognostic insights. The newly introduced PET LVEF reserve (LVEF-R) measures the difference between stress and rest LVEF, creating an ...
Agreement aims to help make clinical trials more efficient and lead to faster advances in patient care
Low socioeconomic status can negatively impact children’s health in preschool, along with their ability to follow specialized health education intervention programs, Mount Sinai researchers found in an international study focused on health ...
The Icahn School of Medicine at Mount Sinai announced today that it has signed a memorandum of understanding with the Brazilian Clinical Research Institute (BCRI) to focus on advancing cardiovascular disease research, innovation, and medical education.
Using optical coherence tomography (OCT) to guide stent implantation during percutaneous coronary intervention (PCI) may be safer and lead to better outcomes for heart disease patients than angiography-guided PCI alone, the most commonly used method.
Join Mount Sinai and Earn CME Credits at the Grown-Up Childhood Heart Disease Event
Mount Sinai Heart, Mount Sinai Children’s Heart Center, and the Mount Sinai Adult Congenital Heart Disease Center are proud to present a special two-day academy on “Grown-Up Childhood Heart Disease for the Adult Cardiologist” in partnership ...
Polypill includes three active ingredients and is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this population.
A study offers evidence that aggressive lipid lowering with a PCSK9 inhibitor, along with a statin, can significantly reduce that threat and potentially help doctors identify patients who would benefit most from treatment to change their ...
Mount Sinai Queens Opens New Cardiac Catheterization Lab to Expedite Care for Heart Attack Patients
Mount Sinai Queens today announced the opening of a new cardiac catheterization lab that will provide rapid and comprehensive care to hundreds of heart patients every year for life-threatening emergencies and scheduled cardiac procedures.
Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status.
Research Links Severe Acute Myocarditis to Cardiomyopathy Genes
Why do some children experience severe acute myocarditis (AM) when other children infected with the same virus have routine illness?
Annapoorna S. Kini, MD, Reports on Latest YELLOW III Study Results
Twenty-six weeks of PCSK9 inhibitor therapy on top of maximally tolerated statins increases markers of plaque stability in patients with stable coronary artery disease, according to the YELLOW III trial, led by Annapoorna S. Kini, MD, ...
Mount Sinai Is Enhancing Its Focus on Women’s Cardiovascular Health
Mount Sinai Heart is launching a multispecialty Women's Heart and Vascular Center, with clinics specifically designed to screen, assess, and educate women about their level of individual risk
App Improves Response Time and Quality of Care for Patients With STEMI
To improve outcomes of STEMI patients, Mount Sinai Heart developed a secure mobile app to streamline real-time communication and coordination between multiple teams.
A unique Mount Sinai study focused on a multiethnic, underserved community in Harlem found that young non-Hispanic Black adult participants were twice as likely to have atherosclerosis as young Hispanic adults.
Polypill Reduces Cardiovascular Mortality by 33 Percent in Patients Treated After a Heart Attack
In a milestone in cardiovascular medicine, a three-drug medication known as a “polypill” was found effective in preventing adverse events such as heart attacks or stroke in people who have previously had a heart attack...
Small Interfering RNA Significantly Reduces Lipoprotein(a) in Cardiovascular Disease
Higher concentrations of lipoprotein(a) have long been associated with atherosclerosis and aortic stenosis, but no drug therapies that lower this concentration are approved. Olpasiran shows promise.
Patients identified by nuclear stress testing as having severe stress-induced myocardial ischemia are likely to benefit from heart bypass surgery or angioplasty, while those with mild or no ischemia are not.
The Center for Inherited Cardiovascular Diseases was established in 2022, positioning Mount Sinai Heart at the forefront of cardiovascular genomic medicine.
Chronic, insufficient sleep can negatively affect immune cells, which may lead to inflammatory disorders and cardiovascular disease, according to a study from the Icahn School of Medicine at Mount Sinai.
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo PCI, and can lower the risk of death or major bleeding by 31 percent.
With a New Generation of Leadership, Mount Sinai Heart Positions Itself for Continued Excellence
Globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position. Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has been named Director.
Research Roundup: Cardiovascular Research Institute Advances Knowledge of Heart Health
The Cardiovascular Research Institute is building on Mount Sinai’s legacy of discovery and innovation with a renewed focus on lifestyle and prevention, systems physiology and bioengineering, and genetic medicine.
Reduced Hospitalizations and Mortality Rates Among COVID-19-Vaccinated Patients With Heart Failure
The study is the first to look at COVID-19 vaccination status and outcomes in patients with heart failure and has indicated significant protective effects in this high-risk patient population.
Genetic Causes of Three Previously Unexplained Rare Diseases Identified
Mount Sinai researchers help identify previously unknown genetic causes of primary lymphedema, thoracic aortic aneurysm disease, and congenital deafness.
Mount Sinai Heart Specialty Report 2023
Message From the President: I am honored to update you on a year of high achievement at Mount Sinai Heart, which is driven by a unified mission—better control and prevention of heart disease.
A novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of acute pancreatitis.
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
ACC Cardiology Hour From ACC.23
Join Valentín Fuster, MD, PhD, MACC and a panel of experts for a discussion on the top late-breaking clinical trials released during the ACC 2023 Conference.
Mount Sinai Study Shows Skipping Breakfast May Compromise the Immune System
Fasting may be detrimental to fighting off infection, and could lead to an increased risk of heart disease, according to a new study by the Icahn School of Medicine at Mount Sinai.
Valentin Fuster, MD, PhD, Receives Prestigious Award from City of Barcelona, Spain
Mount Sinai Heart President given top honor for his extraordinary scientific achievements.
Mount Sinai study could change the treatment course for hundreds of thousands of patients, saving lives and preventing complications.
The award recognizes Dr. Mehran’s outstanding record of effectively mentoring women cardiologists and underscores the importance of mentoring in the professional development of women.
Deepak L. Bhatt, MD, MPH, Named Director of Mount Sinai Heart
Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has been named Director of Mount Sinai Heart.
Valentín Fuster, MD, PhD, Named President of Mount Sinai Heart
Mount Sinai Health System’s globally acclaimed cardiologist Valentín Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position, effective Sunday, January 1, 2023.
The TCT Career Achievement Award has been presented to Valentin Fuster, MD, PhD, today, September 17, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).
Mount Sinai study could lead to ongoing health monitoring of astronauts to assess possible health risks and prevent disease progression.
Roundtable Discussion: ACC Cardiology Hour From ESC Congress 2022
Join Valentín Fuster, MD, and a panel of experts discussing key studies from ESC Congress 2022
Mount Sinai's Roxana Mehran, MD - Women in Leadership: At the Helm of a Major Cardiac Society
Roxana Mehran, MD Discusses Women in Leadership at the ESC
Valentín Fuster, MD discusses the Polypill in findings from the SECURE Trial
In a milestone in cardiovascular medicine, a three-drug medication known as a “polypill” was found effective in preventing adverse events such as heart attacks or stroke in people who have previously had a heart attack
Mount Sinai Cardio-Oncology Program Receives Highest Designation for Excellence
The Cardio-Oncology Program at The Mount Sinai Hospital, under the directorship of Gagan Sahni, MD, has been awarded Gold Center of Excellence status. This is the highest designation of certification from the International Cardio-Oncology ...
A unique Mount Sinai study focused on a multiethnic, underserved community in Harlem found that young non-Hispanic Black adult participants were twice as likely to have atherosclerosis as young Hispanic adults.
Heart failure patients who are unvaccinated against SARS-CoV-2, the virus that causes COVID-19, are three times more likely to die if infected with the virus compared to fully boosted heart failure patients, according to new research out of Mount Sinai Heart.
Mount Sinai Heart: Cardiac Catheterization Laboratory Clinical Outcomes and Innovation Report
We are proud to present this 2021 edition of our "Clinical Outcomes and Innovations Report".
CAD was not associated with a higher risk of NACE or major bleeding at 30 days after TAVR
Chronic thrombocytopenia was not associated with a higher risk of NACE or major bleeding after TAVR
The study evaluates the treatment effects of ticagrelor monotherapy in patients with an increasing number of high-risk criteria
Mount Sinai Heart leader was recognized for his exceptional achievements at the 71st annual ACC conference.
All physicians will receive their awards during a convocation ceremony on April 4.
Mount Sinai Adult Congenital Heart Disease Center Earns Accreditation as a Comprehensive Care Center
In recognition of its expertise in treating adults with congenital heart disease (ACHD), the Mount Sinai Adult Congenital Heart Disease Center has been accredited by the Adult Congenital Heart Association (ACHA) as a Comprehensive Care Center.
The Food and Drug Administration (FDA) in February 2021 approved evinacumab as an add-on treatment for patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol.
Mount Sinai Team Pioneers a Multidisciplinary Treatment of Mitral Valve Prolapse
A team at Mount Sinai Heart has developed a novel approach integrating open-heart cryoablation and mitral valve repair during one operation.
A pioneering program to promote lifelong cardiovascular health in children starting in kindergarten is being expanded by Mount Sinai Heart to schools across the five boroughs of New York City following a successful pilot in spring 2021.
Mount Sinai Heart Specialty Report 2022
This year, The Mount Sinai Hospital was ranked among the top 6 in the nation for cardiology and cardiac surgery, according to U.S. News & World Report, and ranked No. 4 in the world by Newsweek.
Mount Sinai leads international anticoagulation trial for answers on preventing clots in mild hospitalization cases
A Heart to Heart from the Women of Mount Sinai Heart
Join our Mount Sinai Health System Heart leaders as we recognize American Heart Association’s National Go Red Day
Thailand’s “Prince Mahidol Award” recognizes Valentín Fuster, MD, PhD for his exemplary work in cardiovascular health and disease
Implementing school-based programs aimed at teaching healthy cardiovascular health habits as early as preschool can achieve lasting lifestyle changes in children, according to a review published today in the Journal of the American College of Cardiology.
A new, updated risk score can help predict possible contrast-associated acute kidney injury (CA-AKI) among patients undergoing percutaneous coronary intervention (PCI), Mount Sinai researchers report.
Study outlines better way to identify where stents are necessary
Scientists Show How AI May Spot Unseen Signs of Heart Failure
Mount Sinai study suggests a new self-learning algorithm may detect blood pumping problems by reading electrocardiograms
Direct Reprogramming Induces Vascular Regeneration Post Muscle Ischemic Injury
Using direct reprogramming with modified mRNA to induce vascular regeneration in a mouse model of ischemic muscle injury
Roxana Mehran, MD: driving force in women's cardiovascular health
As the Endowed Chair of Cardiovascular Research and Outcomes at the Icahn School of Medicine at Mount Sinai, Roxana Mehran, MD, is the lead Commissioner of the Lancet women and cardiovascular disease Commission
ACC Cardiology Hour From ACC.21 With Dr. Valentín Fuster
Valentín Fuster, MD, PhD, Director of Mount Sinai Heart, Physician-in-Chief of The Mount Sinai Hospital in New York, and Editor-in-Chief of JACC, hosts the annual Cardiology Hour and includes commentary on multiple late-breaking clinical ...
Mount Sinai Heart Specialty Report 2021
Message From Valentin Fuster, MD, PhD, Director of Mount Sinai Heart
In this downloadable PDF, Healio summarizes an article from the Journal of the American College of Cardiology, which reviews the current global landscape for cardiovascular disease and its risk factors.
Cardiovascular Surgery Content |view more
The specialized and complex Ross procedure is the optimal treatment for adolescents and adults with a diseased aortic valve, replacing it with the patient’s own pulmonary valve, resulting in improved long-term life expectancy and less ...
Transcatheter mitral valve repair for heart failure patients with mitral regurgitation can reduce the long-term rate of hospitalizations by almost 50 percent, and death by nearly 30 percent, compared with heart failure patients who don’t undergo the procedure.
Mount Sinai Fuster Heart Hospital 2024
Mount Sinai Fuster Heart Hospital is renowned internationally in all facets of cardiology care, cardiac surgery, and advanced research. Global leaders in cardiology, the team of award-winning physicians has invigorated the science of cardiovascular ...
Mount Sinai Offers Leadless Dual-Chamber Pacemaker, Capping a Decade of Pioneering Work
A journey that began 10 years ago for Vivek Reddy, MD, with his implantation of the country’s first single-chamber leadless cardiac pacemaker, reached fruition as the FDA approved the first dual-chamber device for the treatment of bradycardia, ...
$10.2 Million NIH Grant to Explore the Early Signs of Arrhythmic Mitral Valve Prolapse
A multidisciplinary team is investigating risk factors for malignant ventricular arrhythmias in mitral valve prolapse, which can lead to sudden death in a small but significant subset of patients.
Risk factors for sudden cardiac death from arrhythmic mitral valve prolapse (Part 1)
Arrhythmic mitral prolapse has been identified as a potential cause of sudden cardiac death among some patients with primary mitral regurgitation.
Why mitral valve repair surgery is the safest fix for primary mitral regurgitation
Review a six-year study of over 53,000 patients revealing safety and durability of mitral valve repairs for primary mitral regurgitation.
Treating secondary mitral valve regurgitation and heart failure
Secondary mitral valve regurgitation increases the dangers of heart failure, and the two conditions are often encountered together.
Mitral Valve Repair for Native Mitral Valve Endocarditis
Surgical video from a case study, exploring the complexity of diagnosing mitral valve endocarditis.
Mitral Annular Calcification (MAC): An Algorithmic Approach to Diagnosis and Treatment
Review Mount Sinai’s proven algorithm for determining the best treatment for MAC, with imaging and video.
Left Ventricular Pseudoaneurysm: A Surprising Case Study
Review the challenging case of a left ventricular pseudoaneurysm in a 48-year-old woman presenting with chest pain.
Diagnosing and treating arrhythmic mitral valve prolapse to avoid sudden cardiac death (part 2)
In Part 2 of our discussion, a case study offers new insights into properly identifying, diagnosing and treating high-risk patients.
The department received the highest three-star ratings across all measurable categories in the STS Adult Cardiac Surgery Database, the national benchmark to assess excellence in cardiovascular surgery outcomes.
David H. Adams: 2023 AATS Mitral Conclave - Highlights and Insights
Dr. Randolph Martin discusses the 2023 AATS Mitral Conclave with Co-Program Director, Dr. David Adams. Over 900 registrants from over 50 countries came together to share best practices for taking care of patients with mitral valve disease
Gilbert Tang and Rebecca Hahn: Importance of Imaging to Structural Programs and Role in Selection
Dr. Randolph Martin speaks with Drs. Gilbert Tang and Rebecca Hahn about the importance of imaging in structural heart and valve programs
Randolph Martin, MD, speaks with Ismail El-Hamamsy, MD, and Maral Ouzounian, MD, about the lifetime management of patients with aortic stenosis and aortic insufficiency
Anelechi Anyanwu, MD and Enoch Akowuah, MD: UK Minimitral
Dr. Randolph Martin speaks with Drs. Anyanwu and Akowuah about the UK Minimitral Trial
Anelechi Anyanwu, MD and Gilles Dreyfus, MD: 40-Year Anniversary of the French Correction
Drs. Randolph Martin, Gilles Dreyfus, and Anelechi Anyanwu, discuss the impact of Carpentier’s milestone paper “The French Correction” 40 years after its publication
Transcatheter Repair for Patients with Tricuspid Regurgitation Is Found Superior to Medical Therapy
A breakthrough study found that the TriClip™ transcatheter edge-to-edge repair (TEER) system was safe for patients with severe tricuspid regurgitation, reduced the severity of tricuspid regurgitation, and was associated with an improvement in quality of life.
The Society for Cardiovascular Angiography & Interventions (SCAI) has named George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, at the Icahn School of Medicine at Mount Sinai as its new President.
Mount Sinai Heart: Cardiac Catheterization Laboratory Clinical Outcomes and Innovation Report
We are proud to present the 2022 edition of our Clinical Outcomes and Innovations Report.
First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).
For 24th Year, Mount Sinai Receives Top Safety Rating for Cardiac Catheterization
For the 24th consecutive year, The Mount Sinai Hospital’s Cardiac Catheterization Laboratory or its interventionalists have received the highest two-star safety rating from the New York State Department of Health (NYSDOH) for percutaneous ...
At ACC.23, Deepak L. Bhatt, MD, MPH, Discusses Results of the HALO Trial
Deepak Bhatt, MD, MPH, Director of Mount Sinai Heart, outlines the results for the HALO trial, explaining that a post hoc analysis revealed that a cluster of patients in one of the study arms was nonadherent; when results for adherent ...
Mount Sinai Is Enhancing Its Focus on Women’s Cardiovascular Health
Mount Sinai Heart is launching a multispecialty Women's Heart and Vascular Center, with clinics specifically designed to screen, assess, and educate women about their level of individual risk
Mount Sinai Pioneers Multi-Surgeon Surgical Approach to Marfan and Other Connective Tissue Syndromes
The approach, in which some of the world’s top experts in valve reconstruction perform different aspects of a patient’s heart surgery, is unique.
First-in-Human Study of a New Pulsed Field Ablation System for Atrial Fibrillation
Pulsed field ablation represents a potential paradigm shift in AF ablation. The modality is a more tissue-specific form of energy delivery than thermal, involving the application of high-intensity direct current pulses of short duration ...
Breakthrough findings from a study led by Mount Sinai researchers could improve outcomes for high-risk patients.
Samin Sharma, MD, Named Director of the Mount Sinai Cardiovascular Clinical Institute
Samin K. Sharma, MD, has been named Director of the Mount Sinai Cardiovascular Clinical Institute.
Chronic, insufficient sleep can negatively affect immune cells, which may lead to inflammatory disorders and cardiovascular disease, according to a new study from the Icahn School of Medicine at Mount Sinai.
A large-scale international study led by Mount Sinai has yielded the first risk score that can help predict mortality for patients with atrial fibrillation (AFib) who have undergone a successful transcatheter aortic valve replacement (TAVR) ...
This large study of patients undergoing PET MPI demonstrated that although reduced MBFR was more prevalent in women compared with men, there were no sex-specific differences in the prognostic value of reduced MBFR.
This study reviews the need for a separate risk threshold with PET and SPECT while selecting a high-risk population as the target for an intervention.
Patients with chronic kidney disease (CKD) are more likely to sustain adverse cardiac events following percutaneous coronary intervention (PCI).
Use of anatomic testing such as coronary artery calcium scoring (CACS) of 0 to avoid myocardial perfusion imaging in symptomatic patients could lead to missing microvascular dysfunction in 4 out of 10 patients, a finding associated with a high mortality risk.
Patient Liba’s Case: Mount Sinai Repairs Two Heart Valves in One Procedure
A Mount Sinai surgery team was able to repair both the child's aortic and mitral valves during the same operation.
Ross Procedure Leads to Improved Survival in Adults Undergoing Aortic Valve Surgery
The Ross procedure may be a more favorable option for aortic valve replacement among patients under 50 years old than more standard mechanical or biological replacements, according to a study from Mount Sinai Heart.
Outline Provides Guidance for Management of Heart Failure Patients During COVID-19 Pandemic
A scientific statement outlining unique considerations and suggestions for managing heart failure patients during the COVID-19 pandemic was issued in September 2021 by the Heart Failure Society of America, and Anuradha Lala, MD, Assistant ...
Risk Score to Help Predict Possible Contrast-Associated Kidney Injury After PCI
An updated risk score can help predict possible contrast-associated acute kidney injury (CA-AKI) among patients undergoing percutaneous coronary intervention (PCI), according to Mount Sinai Heart researchers, led by Roxana Mehran, MD, ...
Study of Single-Chamber Leadless Pacemaker Sets Stage for Two-Chamber System
A study showing the safety and effectiveness of a leadless cardiac pacemaker for right ventricular pacing has set the stage for research into a novel dual-chamber device that would serve a significantly broader population of patients with ...
Use of Novel Technique to Measure Artery Blockages Leads to Improved Outcomes After PCI
Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure the severity of artery blockages can lead to significantly improved outcomes after percutaneous coronary intervention (PCI), according ...
Renowned Cardiovascular Immunology Researcher Leads New Cardiovascular Research Institute
Filip Swirski, PhD, an internationally recognized leader in cardiovascular immunology research, is the inaugural Director of the new Cardiovascular Research Institute.
The Ross Procedure Leads to Improved Survival in Adults Undergoing Aortic Valve Surgery
Study shows better outcomes and fewer complications compared to mechanical or biological aortic valve replacement
Myocardial perfusion imaging (MPI) identifies abnormalities that occur early in the ischemic cascade leading to angina.
Don’t Forget to Register for the Mount Sinai Advanced Innovations in Heart Failure Symposium
Mount Sinai Innovations in Heart Failure Virtual Symposium on Friday, January 21, 2022
Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial
Mount Sinai Launches Mobile App to Optimize Care for Heart Attack Patients
Unique technology enhances outcomes during life-threatening emergencies
The Icahn School of Medicine at Mount Sinai will help lead and launch the first clinical trial focusing on women and minority populations to determine which coronary revascularization procedure best improves their survival and quality of life.
The Ross Procedure: Step-by-Step Technique to Optimize Long-term Durability
Ismail El-Hamamsy, MD, PhD, Professor of Cardiovascular Surgery, discusses The Ross Procedure, providing a step-by-step guide to optimize long-term durability and reviews what is new in the literature on this procedure.
Aortic Valve Surgery in Non-Elderly Adults: What's New?
Join Ismail El-Hamamsy, MD, PhD, as he discusses the latest in aortic valve surgery in non-elderly adults, and reviews what is new in the literature on this topic
Bicuspid Aortic Valve Patients: What Are Your Options?
Mount Sinai aortic valve specialists discuss bicuspid aortic valves, the issues they may present, and options for patients
Anticoagulation Associated With Improved Outcomes in Hospitalized COVID-19 Patients
In this study published by the ACC, researchers analyzed the association between in-hospital anticoagulation administration and mortality among patients hospitalized with COVID-19.
David Adams, MD, introduces Prosthetic Heart Valve Replacement presentation
Dr. Adams presents Dr. Anyanwu, who explores the options and tradeoffs in aortic valve replacement, and the issues that should be discussed between doctor and patient.
Valentin Fuster, MD, PhD, presents the ACC Cardiology Roundtable
Get an overview from Dr. Fuster of some of the most impactful studies presented at the national meeting of the American College of Cardiology last year in Orlando.
Mount Sinai Heart Awarded Prestigious Certification by The Joint Commission
Mount Sinai Heart at The Mount Sinai Hospital has earned The Joint Commission’s Comprehensive Cardiac Center (CCC) Certification, becoming one of only four cardiac organizations in the United States to hold the prestigious honor.